We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In Phase II clinical trials, Pegylated Interferon alpha – 2b increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients.
In 19 out of 20 patients, a single 1 mcg/kg dose of the drug demonstrated viral clearance as assessed by RT-PCR and a significant improvement in clinical symptoms, informs the company.